References
Key articles
Skalet AH, Gombos DS, Gallie BL, et al. Screening children at risk for retinoblastoma: consensus report from the American Association of Ophthalmic Oncologists and Pathologists. Ophthalmology. 2018 Mar;125(3):453-8.Full text Abstract
de Graaf P, Goricke S, Rodjan F, et al. Guidelines for imaging retinoblastoma: imaging principles and MRI standardization. Pediatr Radiol. 2012 Jan;42(1):2-14.Full text Abstract
American College of Radiology. ACR appropriateness criteria: orbits, vision and visual loss. 2017 [internet publication].Full text Abstract
Kamihara J, Bourdeaut F, Foulkes WD, et al. Retinoblastoma and neuroblastoma predisposition and surveillance. Clin Cancer Res. 2017 Jul 1;23(13):e98-e106.Full text Abstract
Hutchinson AK, Morse CL, Hercinovic A, et al. Pediatric eye evaluations preferred practice pattern. Ophthalmology. 2023 Mar;130(3):P222-70.Full text Abstract
Gobin YP, Dunkel IJ, Marr BP, et al. Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol. 2011 Jun;129(6):732-7. Abstract
Reference articles
1. Villegas VM, Hess DJ, Wildner A, et al. Retinoblastoma. Curr Opin Ophthalmol. 2013 Nov;24(6):581-8 Abstract
2. National Organization for Rare Disorders. Rare diseases database. Retinoblastoma. 2017 [internet publication].Full text
3. Schefler AC, Abramson DH. Retinoblastoma: what is new in 2007-2008. Curr Opin Ophthalmol. 2008 Nov;19(6):526-34. Abstract
4. Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin N Am. 2005;18:41-53. Abstract
5. Abramson DH, Schefler AC. Update on retinoblastoma. Retina. 2004 Dec;24(6):828-48. Abstract
6. Ballarati L, Elena Rossi E, Bonati MT, et al. 13q deletion and central nervous system anomalies: further insights from karyotype - phenotype analyses of 14 patients. J Med Genet. 2007;44:e60. Abstract
7. Tamboli A, Podgor MJ, Horm JW. The incidence of retinoblastoma in the United States: 1974 through 1985. Arch Ophthalmol. 1990 Jan;108(1):128-32. Abstract
8. Augsburger JJ, Oehlschlager U, Manzitti JE. Multinational clinical and pathologic registry of retinoblastoma. Retinoblastoma International Collaborative Study report 2. Graefes Arch Clin Exp Ophthalmol. 1995 Aug;233(8):469-75. Abstract
9. Mastrangelo D, De Francesco S, Di Leonardo A, et al. Does the evidence matter in medicine? The retinoblastoma paradigm. Int J Cancer. 2007 Dec 1;121(11):2501-5.Full text Abstract
10. Dimaras H, Khetan V, Halliday W, et al. Loss of RB1 induces non-proliferative retinoma; increasing genomic instability correlates with progression to retinoblastoma. Hum Mol Genet. 2008 May 15;17(10):1363-72. Abstract
11. Houston SK, Pina Y, Clarke J, et al. Regional and temporal differences in gene expression of LH(BETA)T(AG) retinoblastoma tumors. Invest Ophthalmol Vis Sci. 2011 Jul 23;52(8):5359-68.Full text Abstract
12. Leiderman YI, Kiss S, Mukai S. Molecular genetics of RB1 - the retinoblastoma gene. Semin Ophthalmol. 2007 Oct-Dec;22(4):247-54. Abstract
13. Orjuela M, Castaneda VP, Ridaura C, et al. Presence of human papilloma virus in tumor tissue from children with retinoblastoma: an alternative mechanism for tumor development. Clin Cancer Res. 2000 Oct;6(10):4010-6.Full text Abstract
14. Dryja TP, Mukai S, Petersen R, et al. Parental origin of mutations of the retinoblastoma gene. Nature. 1989 Jun 15;339(6225):556-8. Abstract
15. DerKinderen DJ, Koten JW, Tan KE, et al. Parental age in sporadic hereditary retinoblastoma. Am J Ophthalmol. 1990 Dec 15;110(6):605-9. Abstract
16. Matsunaga E, Minoda K, Sasaki MS. Parental age and seasonal variation in the births of children with sporadic retinoblastoma: a mutation-epidemiologic study. Hum Genet. 1990 Jan;84(2):155-8. Abstract
17. Ajioka I, Dyer MA. A new model of tumor susceptibility following tumor suppressor gene activation. Cell Cycle. 2008 Mar 15;7(6):735-40. Abstract
18. Xu K, Rosenwaks Z, Beaverson K, et al. Preimplantation genetic diagnosis for retinoblastoma: the first reported liveborn. Am J Ophthalmol. 2004 Jan;137(1):18-23. Abstract
19. Skalet AH, Gombos DS, Gallie BL, et al. Screening children at risk for retinoblastoma: consensus report from the American Association of Ophthalmic Oncologists and Pathologists. Ophthalmology. 2018 Mar;125(3):453-8.Full text Abstract
20. Truong B, Green AL, Friedrich P, et al. Ethnic, racial, and socioeconomic disparities in retinoblastoma. JAMA Pediatr. 2015 Dec;169(12):1096-104. Abstract
21. Donahue SP, Baker CN, Committee on Practice and Ambulatory Medicine, American Academy of Pediatrics, et al. Procedures for the evaluation of the visual system by pediatricians. Pediatrics. 2016 Jan;137(1):e20153597.Full text Abstract
22. Vigoda MM, Latiff A, Murray TG, et al. Can children undergoing ophthalmologic examinations under anesthesia be safely anesthetized without using an IV line? Clin Ophthalmol. 2011;5:503-8.Full text Abstract
23. Houston SK, Berrocal AM, Murray TG. The future of diagnostic imaging in retinoblastoma. J AAPOS. 2011 Apr;15(2):125-6. Abstract
24. de Graaf P, Goricke S, Rodjan F, et al. Guidelines for imaging retinoblastoma: imaging principles and MRI standardization. Pediatr Radiol. 2012 Jan;42(1):2-14.Full text Abstract
25. American College of Radiology. ACR appropriateness criteria: orbits, vision and visual loss. 2017 [internet publication].Full text Abstract
26. Rauschecker AM, Patel CV, Yeom KW, et al. High-resolution MR imaging of the orbit in patients with retinoblastoma. Radiographics. 2012 Sep-Oct;32(5):1307-26.Full text Abstract
27. Mohney BG, Robertson DM. Ancillary testing for metastasis in patients with newly diagnosed retinoblastoma. Am J Ophthalmol. 1994 Dec 15;118(6):707-11. Abstract
28. Kamihara J, Bourdeaut F, Foulkes WD, et al. Retinoblastoma and neuroblastoma predisposition and surveillance. Clin Cancer Res. 2017 Jul 1;23(13):e98-e106.Full text Abstract
29. Silva RA, Dubovy SR, Fernandes CE, et al. Retinoblastoma with Coats' response. Ophthalmic Surg Lasers Imaging. 2011 Dec 16;42 Online:e139-43. Abstract
30. Hutchinson AK, Morse CL, Hercinovic A, et al. Pediatric eye evaluations preferred practice pattern. Ophthalmology. 2023 Mar;130(3):P222-70.Full text Abstract
31. Gerrish A, Bowns B, Mashayamombe-Wolfgarten C, et al. Non-invasive prenatal diagnosis of retinoblastoma inheritance by combined targeted sequencing strategies. J Clin Med. 2020 Oct 30;9(11):3517.Full text Abstract
32. Royal College of Pathologists. Standards and datasets for reporting cancers. Dataset for histopathological reporting of ocular retinoblastoma. January 2018 [internet publication].Full text
33. Schefler AC, Cicciarelli N, Feuer W, et al. Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation. Ophthalmology. 2007 Jan;114(1):162-9. Abstract
34. Gobin YP, Dunkel IJ, Marr BP, et al. Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol. 2011 Jun;129(6):732-7. Abstract
35. Chen Q, Zhang B, Dong Y, et al. Comparison between intravenous chemotherapy and intra-arterial chemotherapy for retinoblastoma: a meta-analysis. BMC Cancer. 2018 Apr 27;18(1):486.Full text Abstract
36. Ministry of Health and Family Welfare India. Retinoblastoma: standard treatment guidelines. 2016 [internet publication].Full text
37. Houston SK, Wykoff CC, Berrocal AM, et al. Lasers for the treatment of intraocular tumors. Lasers Med Sci. 2013 May;28(3):1025-34. Abstract
38. Scott IU, Murray TG, Feuer WJ, et al. External beam radiotherapy in retinoblastoma: tumor control and comparison of 2 techniques. Arch Ophthalmol. 1999 Jun;117(6):766-70. Abstract
39. Abramson DH, Beaverson KL, Chang ST, et al. Outcome following initial external beam radiotherapy in patients with Reese-Ellsworth group Vb retinoblastoma. Arch Ophthalmol. 2004 Sep;122(9):1316-23. Abstract
40. Leng T, Cebulla CM, Schefler AC, et al. Focal periocular carboplatin chemotherapy avoids systemic chemotherapy for unilateral, progressive retinoblastoma. Retina. 2010;30(suppl 4):S66-S68. Abstract
41. Mulvihill A, Budning A, Jay V, et al. Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma. Arch Ophthalmol. 2003 Aug;121(8):1120-4. Abstract
42. Schmack I, Hubbard GB, Kang SJ, et al. Ischemic necrosis and atrophy of the optic nerve after periocular carboplatin injection for retinoblastoma. Am J Ophthalmol. 2006 Aug;142(2):310-5. Abstract
43. Uusitalo MS, Van Quill KR, Scott IU, et al. Evaluation of chemoprophylaxis in patients with unilateral retinoblastoma with high-risk features on histopathologic examination. Arch Ophthalmol. 2001 Jan;119(1):41-8. Abstract
44. Chantada GL, Dunkel IJ, de Dávila MT, et al. Retinoblastoma patients with high risk ocular pathological features: who needs adjuvant therapy? Br J Ophthalmol. 2004 Aug;88(8):1069-73.Full text Abstract
45. Zelter M, Damel A, Gonzalez G, et al. A prospective study on the treatment of retinoblastoma in 72 patients. Cancer. 1991 Oct 15;68(8):1685-90. Abstract
46. Kiratli H, Bilgiç S, Ozerdem U. Management of massive orbital involvement of intraocular retinoblastoma. Ophthalmology. 1998 Feb;105(2):322-6. Abstract
47. Goble RR, McKenzie J, Kingston JE, et al. Orbital recurrence of retinoblastoma successfully treated by combined therapy. Br J Ophthalmol. 1990 Feb;74(2):97-8.Full text Abstract
48. Doz F, Khelfaoui F, Mosseri V, et al. The role of chemotherapy in orbital involvement of retinoblastoma: the experience of a single institution with 33 patients. Cancer. 1994 Jul 15;74(2):722-32. Abstract
49. Sandri A, Besenzon L, Acquaviva A, et al. "Eight drugs in one day" chemotherapy in a nonfamilial bilateral retinoblastoma with recurrent cerebrospinal fluid metastases. Pediatr Hematol Oncol. 1998 Nov-Dec;15(6):557-61. Abstract
50. Doz F, Neuenschwander S, Plantaz D, et al. Etoposide and carboplatin in extraocular retinoblastoma: a study by the Société Française d'Oncologie Pédiatrique. J Clin Oncol. 1995 Apr;13(4):902-9. Abstract
51. Namouni F, Doz F, Tanguy ML, et al. High-dose chemotherapy with carboplatin, etoposide and cyclophosphamide followed by a haematopoietic stem cell rescue in patients with high-risk retinoblastoma: a SFOP and SFGM study. Eur J Cancer. 1997 Dec;33(14):2368-75. Abstract
52. White L. Chemotherapy for retinoblastoma. Med Pediatr Oncol. 1995 May;24(5):341-2. Abstract
53. Schouten-Van Meeteren AY, Moll AC, Imhof SM, et al. Overview: chemotherapy for retinoblastoma: an expanding area of clinical research. Med Pediatr Oncol. 2002 Jun;38(6):428-38. Abstract
54. Matsubara H, Makimoto A, Higa T, et al. A multidisciplinary treatment strategy that includes high-dose chemotherapy for metastatic retinoblastoma without CNS involvement. Bone Marrow Transplant. 2005 Apr;35(8):763-6. Abstract
55. Kremens B, Wieland R, Reinhard H, et al. High-dose chemotherapy with autologous stem cell rescue in children with retinoblastoma. Bone Marrow Transplant. 2003 Feb;31(4):281-4. Abstract
56. Hertzberg H, Kremens B, Velten I, et al. Recurrent disseminated retinoblastoma in a 7-year-old girl treated successfully by high-dose chemotherapy and CD34-selected autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 2001 Mar;27(6):653-5. Abstract
57. Dunkel IJ, Aledo A, Kernan NA, et al. Successful treatment of metastatic retinoblastoma. Cancer. 2000 Nov 15;89(10):2117-21. Abstract
58. Shields CL, Shields JA, Cater J, et al. Plaque radiotherapy for retinoblastoma: long-term tumor control and treatment complications in 208 tumors. Ophthalmology. 2001 Nov;108(11):2116-21. Abstract
59. Merchant TE, Gould CJ, Wilson MW, et al. Episcleral plaque brachytherapy for retinoblastoma. Pediatr Blood Cancer. 2004 Aug;43(2):134-9. Abstract
60. Gobin YP, Dunkel IJ, Marr BP, et al. Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol. 2011 Jun;129(6):732-7. Abstract
61. Munier FL, Gaillard MC, Balmer A, et al. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. Br J Ophthalmol. 2012 Aug;96(8):1078-83. Abstract
62. Ghassemi F, Shields CL. Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma. Arch Ophthalmol. 2012 Oct;130(10):1268-71.Full text Abstract
63. Smith SJ, Smith BD. Evaluating the risk of extraocular tumour spread following intravitreal injection therapy for retinoblastoma: a systematic review. Br J Ophthalmol. 2013 Oct;97(10):1231-6. Abstract
64. Shields CL, Douglass AM, Beggache M, et al. Intravitreous chemotherapy for active vitreous seeding from retinoblastoma: outcomes after 192 consecutive injections - the 2015 Howard Naquin lecture. Retina. 2016 Jun;36(6):1184-90. Abstract
65. Francis JH, Brodie SE, Marr B, et al. Efficacy and toxicity of intravitreous chemotherapy for retinoblastoma: four-year experience. Ophthalmology. 2017 Apr;124(4):488-495. Abstract
66. Francis JH, Iyer S, Gobin YP, et al. Retinoblastoma vitreous seed clouds (class 3): a comparison of treatment with ophthalmic artery chemosurgery with or without intravitreous and periocular chemotherapy. Ophthalmology. 2017 May 22 [Epub ahead of print]. Abstract
67. Canadian Ophthalmological Society (Canadian Retinoblastoma Society). National retinoblastoma strategy: Canadian guidelines for care (Stratégie thérapeutique du rétinoblastome guide clinique canadien). Can J Ophthalmol. 2009;44(Suppl 2):S1-S88.Full text Abstract
68. Silva RA, Dubovy SR, Hess D, et al. Hemorrhage as a sign of treatment failure after intra-arterial chemotherapy in retinoblastoma. J AAPOS. 2015 Jun;19(3):268-70. Abstract
69. Rivera GK, Pui CH, Santana VM, et al. Epipodophyllotoxins in the treatment of childhood cancer. Cancer Chemother Pharmacol. 1994;34 Suppl:S89-S95. Abstract
Use of this content is subject to our disclaimer